Travere Therapeutics, Inc. Common Stock
TVTXTravere Therapeutics, Inc. (TVTX) is a biotechnology company focused on developing and commercializing therapies for rare andимmunologic diseases. The company's portfolio includes treatments aimed at addressing unmet medical needs in kidney, liver, and rare neurological disorders. Founded with a mission to improve patient outcomes, Travere leverages its expertise in novel drug discovery and development to bring targeted therapies to market.
Company News
Kuehn Law is investigating whether officers and directors of Travere Therapeutics breached fiduciary duties to shareholders through potential self-dealing. Long-term shareholders may be entitled to damages and corporate governance reforms.
Kuehn Law is investigating whether officers and directors of Rhythm Pharmaceuticals breached fiduciary duties to shareholders through potential self-dealing. Long-term shareholders may be entitled to damages and corporate governance reforms. The law firm is also investigating similar matters at Travere Therapeutics and Viking Therapeutics.
Roy D. Baynes, Director at Travere Therapeutics, exercised and sold 4,500 shares for approximately $210,000 on May 5, 2026, reducing his direct holdings by 10.71%. The sale was executed under a pre-arranged 10b5-1 plan adopted in November 2025 and occurred near the stock's 52-week high. Despite cashing in near the top, Baynes retained 37,500 shar...
The American Kidney Fund (AKF) is launching its Kidney Month campaign on March 1, 2026, to raise awareness about kidney disease affecting 1 in 7 American adults. The campaign emphasizes early detection and prevention through the 'Kidneys Count' initiative and encourages people to pledge to discuss kidney health with their doctors. AKF will host K...
Robbins Geller Rudman & Dowd LLP has launched an investigation into Travere Therapeutics, Inc. for potential violations of U.S. federal securities laws, alleging the biopharmaceutical company and certain executives made materially false and/or misleading statements regarding its business and operations. The firm is seeking investors who suffered ...
